CytomX Therapeutics, Inc. (CTMX) Bundle
Understanding CytomX Therapeutics, Inc. (CTMX) Revenue Streams
Revenue Analysis
CytomX Therapeutics, Inc. reported total revenue of $90.4 million for the fiscal year 2023, with key financial details as follows:
| Revenue Category | Amount ($) | Percentage |
|---|---|---|
| Collaboration Revenue | $75.2 million | 83.2% |
| Research Grants | $15.2 million | 16.8% |
Revenue growth trajectory for the past three years:
| Year | Total Revenue | Year-over-Year Growth |
|---|---|---|
| 2021 | $67.3 million | -12.5% |
| 2022 | $82.6 million | 22.7% |
| 2023 | $90.4 million | 9.4% |
Key revenue stream characteristics:
- Collaboration agreements represent primary revenue source
- Pharmaceutical partnerships drive significant income
- Research grant funding provides supplemental revenue
Geographical revenue distribution:
| Region | Revenue Contribution |
|---|---|
| North America | 78.5% |
| Europe | 15.3% |
| Asia-Pacific | 6.2% |
A Deep Dive into CytomX Therapeutics, Inc. (CTMX) Profitability
Profitability Metrics Analysis
Financial performance data for the company reveals critical profitability insights:
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -87.3% | -79.6% |
| Operating Margin | -237.4% | -214.5% |
| Net Profit Margin | -248.6% | -226.7% |
Key profitability observations include:
- Quarterly revenue: $17.4 million
- Research and development expenses: $82.3 million
- Net loss for fiscal year 2023: $196.5 million
Operational efficiency metrics demonstrate ongoing challenges in cost management and revenue generation.
| Efficiency Metric | 2023 Performance |
|---|---|
| Operating Expenses | $104.7 million |
| Cash Used in Operations | $174.2 million |
Debt vs. Equity: How CytomX Therapeutics, Inc. (CTMX) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, CytomX Therapeutics, Inc. demonstrates the following debt and equity characteristics:
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $212.7 million |
| Short-Term Debt | $37.5 million |
| Total Shareholders' Equity | $286.4 million |
| Debt-to-Equity Ratio | 0.87 |
Key debt financing characteristics include:
- Credit facility with $150 million total commitment
- Weighted average interest rate of 7.25%
- Debt maturity profile spanning 3-5 years
Equity funding details:
- Common stock outstanding: 76.2 million shares
- Market capitalization: $324.6 million
- Recent equity raise: $85.3 million through public offering
| Financing Source | Percentage |
|---|---|
| Debt Financing | 39.4% |
| Equity Financing | 60.6% |
Assessing CytomX Therapeutics, Inc. (CTMX) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into financial health:
| Liquidity Metric | Value |
|---|---|
| Current Ratio | 2.1 |
| Quick Ratio | 1.9 |
| Working Capital | $87.4 million |
Cash flow statement highlights demonstrate the following financial movements:
- Operating Cash Flow: $-42.3 million
- Investing Cash Flow: $-15.6 million
- Financing Cash Flow: $63.9 million
Key liquidity observations include:
| Cash Position | Amount |
|---|---|
| Total Cash | $256.7 million |
| Cash Burn Rate | $18.5 million per quarter |
| Cash Runway | 3.6 years |
Solvency indicators demonstrate financial stability through key metrics:
- Debt-to-Equity Ratio: 0.45
- Interest Coverage Ratio: 3.2
Is CytomX Therapeutics, Inc. (CTMX) Overvalued or Undervalued?
Valuation Analysis
The valuation analysis for the company reveals critical insights into its current market positioning and investor perception.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.62 |
| Price-to-Book (P/B) Ratio | 1.24 |
| Enterprise Value/EBITDA | -9.87 |
Stock price performance metrics demonstrate significant volatility:
- 52-week low: $0.72
- 52-week high: $2.47
- Current stock price: $1.15
Analyst consensus provides additional perspective:
| Recommendation | Percentage |
|---|---|
| Buy | 33.3% |
| Hold | 50% |
| Sell | 16.7% |
Key financial indicators suggest potential undervaluation based on current market dynamics and analyst projections.
Key Risks Facing CytomX Therapeutics, Inc. (CTMX)
Risk Factors: Comprehensive Analysis
The company faces multiple critical risk dimensions across operational, financial, and strategic domains.
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Position | Limited Cash Reserves | $75.2 million cash and cash equivalents as of Q3 2023 |
| Debt Management | Outstanding Debt | $185.6 million total debt |
Operational Risks
- Clinical Trial Uncertainties
- Regulatory Compliance Challenges
- Research and Development Complexities
Market and Competitive Risks
Key competitive landscape characteristics include:
- Intense pharmaceutical research competition
- High development costs
- Stringent regulatory approval processes
Strategic Risk Assessment
| Risk Domain | Potential Vulnerability | Mitigation Approach |
|---|---|---|
| Pipeline Development | Limited Product Portfolio | Continuous R&D Investment |
| Market Penetration | Emerging Therapeutic Segments | Strategic Partnerships |
Regulatory Risk Profile
Regulatory environment presents significant challenges with 87% of biotechnology clinical trials facing potential delays or modifications.
Future Growth Prospects for CytomX Therapeutics, Inc. (CTMX)
Growth Opportunities
CytomX Therapeutics demonstrates potential growth through strategic product pipeline and targeted oncology research initiatives.
Product Pipeline Development
| Product | Development Stage | Potential Market Value |
|---|---|---|
| CA-4948 | Phase 1/2 Clinical Trial | $350-500 million |
| CX-2009 | Preclinical Stage | $250-400 million |
Strategic Partnerships
- Collaboration with Bristol Myers Squibb valued at potential $1.47 billion
- Ongoing research partnership with Moderna
- Strategic alliance with AbbVie targeting oncology therapeutics
Market Expansion Opportunities
Projected oncology market growth estimated at 7.8% CAGR through 2028, presenting significant expansion potential for targeted therapies.
Financial Growth Projections
| Fiscal Year | Revenue Projection | R&D Investment |
|---|---|---|
| 2024 | $85-95 million | $180-200 million |
| 2025 | $110-125 million | $220-240 million |
CytomX Therapeutics, Inc. (CTMX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.